The Journal ofClinical Psychiatry
Information from Industry June 30, 2020
,
This article is freely available to all
https://www.psychiatrist.com/esketamine-ciii-nasal-spray-treatment-resistant-depression/
SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression
Save
Share
Cite
Recent News Articles
SPOTLIGHT
Recent JCP Articles
Recent PCC Articles
Information from Industry